Marinus Pharmaceuticals downgraded by Ladenburg Thalmann
$MRNS
Biotechnology: Pharmaceutical Preparations
Health Care
Ladenburg Thalmann downgraded Marinus Pharmaceuticals from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/23/2024 | $6.00 | Perform → Outperform | Oppenheimer |
| 8/14/2024 | Buy → Neutral | Ladenburg Thalmann | |
| 4/16/2024 | $20.00 → $2.00 | Outperform → Neutral | Robert W. Baird |
| 4/15/2024 | $24.00 → $3.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 8/11/2023 | $14.00 → $9.00 | Outperform → Perform | Oppenheimer |
| 1/20/2023 | $23.00 | Outperform | RBC Capital Mkts |
| 12/20/2021 | $32.00 → $30.00 | Outperform | SVB Leerink |
Oppenheimer upgraded Marinus Pharmaceuticals from Perform to Outperform and set a new price target of $6.00
Ladenburg Thalmann downgraded Marinus Pharmaceuticals from Buy to Neutral
Robert W. Baird downgraded Marinus Pharmaceuticals from Outperform to Neutral and set a new price target of $2.00 from $20.00 previously